GlobeNewswire by notified

Anmodning om ophør af suspension i en afdeling under Investeringsforeningen Danske Invest

24.10.2023 08:57:08 CEST | GlobeNewswire by notified

Del
Nasdaq Copenhagen
Nikolaj Plads 6
1007 København K







Parallelvej 17
2800 Kgs. Lyngby
Telefon 33 33 71 71
Telefax 33 15 71 71
www.danskeinvest.dk

Anmodning om ophør af suspension i en afdeling under Investeringsforeningen Danske Invest
Der anmodes om ophør af suspension for afdelingen/andelsklassen nedenfor.

Investeringsforeningen Danske Invest:

Afdeling/andelsklasseISIN-kode OMX Identifikation
Kina, klasse DKK dDK0010295336DKIKI

Med venlig hilsen

DANSKE INVEST
MANAGEMENT A/S

Tina Hjorth Hetting

Head of Fund Products

For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.

Information om GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg pressemeddelelser fra GlobeNewswire by notified

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra GlobeNewswire by notified

XPENG G9 Achieves a Five-Star 2023 Safety Rating from Euro NCAP6.12.2023 11:00:00 CET | Press release

The new XPENG G9, now on sale in Europe, received a five-star 2023 safety rating from Euro NCAPThis is XPENG's second five-star safety rating for an international model following the new P7 in October; and its first SUV obtained both Euro NCAP and C-NCAP five-star ratings AMSTERDAM, Dec. 06, 2023 (GLOBE NEWSWIRE) -- XPENG Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announces that the international model of their flagship electric SUV, XPENG G9, has received a five-star 2023 safety rating from Euro NCAP. Euro NCAP's five-star safety rating system aims to help consumers, their families and businesses compare vehicles more easily and identify the safest choice for their needs. The tests, which replicate real-life road danger scenarios, represent the European gold standard for comprehensive automotive safety testing. The rating recognises the XPENG G9's advanced body structure and comprehensive passive s

AS Tallink Grupp: Managers’ Transactions6.12.2023 11:00:00 CET | Press release

Person subject to the notification requirement Name: AS Infortar Position: Closely associated person (X) Legal person Person Discharging Managerial Responsibilities in Issuer Name: Hanschmidt, Ain Position: Member of the Supervisory Board Name: Pant, Eve Position: Member of the Supervisory Board Issuer: AS Tallink Grupp LEI: 529900QRMWAKKR3L9W75 Notification type: Initial Notification _____________________________________ Transaction date: 04.12.2023 Venue: Nasdaq OMX Tallinn Instrument type: Share ISIN: EE3100004466 Nature of the transaction: Acquisition Transaction details: (1): Volume: 105,178; Unit price: 0.68 EUR Aggregated transactions: (2): Volume: 105,178; Volume weighted average price: 0.68 EUR Anneli Simm Investor Relations Manager AS Tallink Grupp Sadama 5 10111 Tallinn E-mail Anneli.simm@tallink.ee

CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy6.12.2023 11:00:00 CET | Press release

ZÜRICH, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy (GA). Licensed to Boehringer Ingelheim, BI 771716 is a highly specific antibody fragment of reduced size, enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology. The Phase 1 study (NCT06006585) is evaluating the safety, tolerability and pharmacokinetics of intravitreal single rising doses and multiple doses of BI 771716 as a potential treatment for GA. GA is a chronic and progressive, irreversible retinal disease that occurs in people with late-stage dry age-related macular degeneration (AMD) impacting the ability to see. More than 5 million people worldwide suffer from GA, of which more than 40% are legally blind. GA worsens with age, affecting 1 in 29 people above the age of 75 and 1 in 4 people above 90. Consequently, risi

ForFarmers N.V.: Approval competition authority for the acquisition of Piast Pasze Sp. z.o.o.6.12.2023 10:30:00 CET | Press release

Lochem, 6 December 2023 Approval competition authority for the acquisition of Piast Pasze Sp. z.o.o. Today, ForFarmers received approval from the Polish competition authority to acquire Piast Pasze Sp. z.o.o. ("Piast"). With this transaction, announced on 25 July 2023, ForFarmers/Tasomix's volume in Poland will expand by 410,000 tonnes, strengthening its position in the broiler sector in particular. Parties will work towards a closing of the acquisition. This transaction is in line with ForFarmers/Tasomix's strategic objectives to expand in the attractive Polish agricultural market. This press release contains information that qualifies as inside information within the meaning of Article 7 paragraph 1 of the EU Market Abuse Regulation. Note to the editor / For further information: Floor van Maaren, T: 06-29597746 Paweł Świerkula, Managing Director ForFarmers/Tasomix M + 48 510 22 00 22 • E: pawel.swierkula@tasomix.pl About ForFarmers ForFarmers N.V. is an international organisation tha